Effect of Repeat Vaccination on Immunogenicity of Quadrivalent Cell-Culture and Recombinant Influenza Vaccines Among Healthcare Personnel Aged 18–64 Years: A Randomized, Open-Label Trial
Clinical Infectious Diseases · 08.02.2023 · 76 (3) · e1168-e1176
DOI: 10.1093/cid/ciac683 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 29.08.2022. Verfasst von Manjusha Gaglani und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Baylor Scott & White Health, Temple, Texas, USA. Hauptthemen laut MEDLINE: Influenza A Virus, H1N1 Subtype, Influenza Vaccines, Influenza, Human, Smallpox Vaccine. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CDC HHS, CDC, Abt Associates.
Abstract (Originalsprache)
Background
Antibody responses to non–egg-based standard-dose cell-culture influenza vaccine (containing 15 µg hemagglutinin [HA]/component) and recombinant vaccine (containing 45 µg HA/component) during consecutive seasons have not been studied in the United States.
Methods
In a randomized trial of immunogenicity of quadrivalent influenza vaccines among healthcare personnel (HCP) aged 18–64 years over 2 consecutive seasons, HCP who received recombinant-HA influenza vaccine (RIV) or cell culture–based inactivated influenza vaccine (ccIIV) during the first season (year 1) were re-randomized the second season of 2019–2020 (year 2 [Y2]) to receive ccIIV or RIV, resulting in 4 ccIIV/RIV combinations. In Y2, hemagglutination inhibition antibody titers against reference cell–grown vaccine viruses were compared in each ccIIV/RIV group with titers among HCP randomized both seasons to receive egg-based, standard-dose inactivated influenza vaccine (IIV) using geometric mean titer (GMT) ratios of Y2 post-vaccination titers.
Results
Y2 data from 414 HCP were analyzed per protocol. Compared with 60 IIV/IIV recipients, 74 RIV/RIV and 106 ccIIV/RIV recipients showed significantly elevated GMT ratios (Bonferroni corrected P < .007) against all components except A(H3N2). Post-vaccination GMT ratios for ccIIV/ccIIV and RIV/ccIIV were not significantly elevated compared with IIV/IIV except for RIV/ccIIV against A(H1N1)pdm09.
Conclusions
In adult HCP, receipt of RIV in 2 consecutive seasons or the second season was more immunogenic than consecutive egg-based IIV for 3 of the 4 components of quadrivalent vaccine. Immunogenicity of ccIIV/ccIIV was similar to that of IIV/IIV. Differences in HA antigen content may play a role in immunogenicity of influenza vaccination in consecutive seasons. Clinical Trials Registration NCT03722589.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Baylor Scott & White Health, Temple, Texas, USA.
- Department of Medical Education, Texas A & M University College of Medicine, Temple, Texas, USA.
- Influenza Division of the National Center for Immunization and Respiratory Diseases (NCIRD), Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
- Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon, USA.
- Abt Associates, Atlanta, Georgia, USA.
ORCID-Profile: Manjusha Gaglani, Meredith G Wesley
Förderung
- CDC HHS
- CDC
- Abt Associates
Zitieren
APA
Gaglani, M., Kim, S. S., Naleway, A. L., Levine, M. Z., Edwards, L., Murthy, K., Dunnigan, K., Zunie, T., Groom, H., Ball, S., Jeddy, Z., Hunt, D., Wesley, M. G., Sambhara, S., Gangappa, S., Grant, L., Cao, W., Gross, F. L., Mishina, M., …, & Flannery, B. (2023). Effect of Repeat Vaccination on Immunogenicity of Quadrivalent Cell-Culture and Recombinant Influenza Vaccines Among Healthcare Personnel Aged 18–64 Years: A Randomized, Open-Label Trial. Clinical Infectious Diseases, 76(3), e1168-e1176. https://doi.org/10.1093/cid/ciac683
Vancouver
Gaglani M, Kim SS, Naleway AL, Levine MZ, Edwards L, Murthy K, et al. Effect of Repeat Vaccination on Immunogenicity of Quadrivalent Cell-Culture and Recombinant Influenza Vaccines Among Healthcare Personnel Aged 18–64 Years: A Randomized, Open-Label Trial. Clinical Infectious Diseases. 2023;76(3):e1168-e1176. doi:10.1093/cid/ciac683
BibTeX
@article{Gaglani2023,
author = {Gaglani, Manjusha and Kim, Sara S and Naleway, Allison L and Levine, Min Z and Edwards, Laura and Murthy, Kempapura and Dunnigan, Kayan and Zunie, Tnelda and Groom, Holly and Ball, Sarah and Jeddy, Zuha and Hunt, Danielle and Wesley, Meredith G and Sambhara, Suryaprakash and Gangappa, Shivaprakash and Grant, Lauren and Cao, Weiping and Gross, F Liaini and Mishina, Margarita and Fry, Alicia M and Thompson, Mark G and Dawood, Fatimah S and Flannery, Brendan},
title = {Effect of Repeat Vaccination on Immunogenicity of Quadrivalent Cell-Culture and Recombinant Influenza Vaccines Among Healthcare Personnel Aged 18–64 Years: A Randomized, Open-Label Trial},
journal = {Clinical Infectious Diseases},
year = {2023},
volume = {76},
number = {3},
pages = {e1168--e1176},
doi = {10.1093/cid/ciac683}
}
EUVIMED